联化科技股份有限公司 第八届董事会独立董事专门会议第一次会议决议 独立董事对公司第八届董事会第十六次会议审议的相关议案进行了预审议， 经过审慎分析，基于独立判断，形成以下决议： 一、会议以3票同意，0票反对，0票弃权的表决结果，审议并通过《关于控 股子公司拟申请在新三板挂牌的议案》。 经核查，公司控股子公司上海宝丰申请在新三板挂牌，有利于上海宝丰进一 步完善其法人治理结构，拓宽资本渠道，帮助其业务整合与发展，同时也有利于 上市公司总体经营战略的实施，不存在损害股东和公司利益的情况，不会影响公 司独立上市地位，也不会对公司的持续经营运作产生重大影响。我们同意公司控 股子公司上海宝丰在符合国家相关法律法规政策和各项条件成熟的情况下申请 在新三板挂牌，并提交公司董事会审议。 独立董事：蒋萌、俞寿云、Zhang Yun 2024年6月14日 联化科技股份有限公司第八届董事会独立董事专门会议第一次会议通知于 2024 年 6 月 11 日以电子邮件的方式发出，于 2024 年 6 月 14 日 8 时在本公司会 议室以通讯表决的方式召开，应出席会议独立董事3名，实际出席独立董事3名。 会议的召开符合《中华人民共和国公司 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-036 联化科技股份有限公司 关于控股子公司拟申请在新三板挂牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"联化科技"或"公司"）于2024年6月14 日召开了第八届董事会第十六次会议，审议通过了《关于控股子公司拟申请在新 三板挂牌的议案》，同意公司控股子公司上海宝丰机械制造股份有限公司（以下 简称"上海宝丰"）拟申请在全国中小企业股份转让系统（以下简称"新三板"） 公开转让并挂牌事宜，并授权公司及上海宝丰管理层具体办理上海宝丰新三板挂 牌相关事宜。该议案无需提交公司股东大会审议。现将有关事项公告如下： 一、上海宝丰基本情况 （一）工商登记情况 公司名称：上海宝丰机械制造股份有限公司 公司类型：股份有限公司(非上市、自然人投资或控股) 统一社会信用代码：91310113734085795W 公司住所：上海市宝山区工业路 458 号 法定代表人：彭寅生 注册资本：14,129.8420 万元人民币 成立时间：2001 年 12 月 17 日 与公司的关系：为 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-035 联化科技股份有限公司 第八届董事会第十六次会议决议公告 一、会议以4票同意，0票反对，0票弃权的表决结果，审议并通过《关于控 股子公司拟申请在新三板挂牌的议案》，关联董事彭寅生先生、何春先生、樊小 彬先生回避表决。 公司董事会同意公司控股子公司上海宝丰机械制造股份有限公司（以下简称 "上海宝丰"）拟申请在全国中小企业股份转让系统（以下简称"新三板"）公开 转让并挂牌事宜，并授权公司及上海宝丰管理层具体办理上海宝丰新三板挂牌相 关事宜。 具体详见公司同日刊登于《证券时报》、《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）的《关于控股子公司拟申请在新三板挂牌的公告》（公告 编号：2024-036）。 特此公告。 联化科技股份有限公司董事会 二〇二四年六月十五日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届董事会第十六次会议通 知于2024年6月11日以电子邮件方式发出。会议于2024年6月14日在联化科技会议 室以现场与通讯表 ...

Group 1: Financial Performance - The company's Q1 2023 and Q1 2024 performance was poor, primarily due to the "de-inventory" trend in the plant protection industry, leading to a reduction in orders and revenue decline [1] - The company expects the "de-inventory" trend to slow down in the second half of the year, with a recovery in patented products compared to generic products [1] - The company is actively communicating with clients to maintain strategic relationships and mitigate the impact of "de-inventory" [1] Group 2: Business Development - The company has established a CRO team to enhance customer service and increase client retention, with the CRO business progressing as planned [2] - In the renewable energy sector, the company is conducting R&D and pilot production, aiming to leverage its chemical industry experience for future success [2] - The UK subsidiary is undergoing production line modifications and is actively seeking new clients and products to drive growth [2] Group 3: International Expansion - The company has signed a purchase intention for industrial land in Malaysia and is adjusting the construction schedule based on specific orders [2] - The Malaysian factory and UK subsidiary will work together to enhance international competitiveness and support the "going out" strategy [2] Group 4: ESG Initiatives - The company is implementing ESG measures, particularly in its pharmaceutical subsidiary, which includes carbon emission management [3] - Future ESG efforts will be promoted company-wide based on existing experiences and results, with targeted disclosures to meet regulatory and stakeholder needs [3]

Financial Performance - In 2023, the company achieved an operating revenue of 644,215.28 thousand yuan, a decrease of 18.10% compared to the previous year [1] - The industrial business revenue was 641,015.50 thousand yuan, down 18.41% year-on-year [1] - The total profit was -40,205.38 thousand yuan, a decline of 142.57% compared to the previous year [1] - The net profit attributable to shareholders was -46,524.39 thousand yuan, a decrease of 166.76% year-on-year [1] - In Q1 2024, the company reported an operating revenue of 146,559.74 thousand yuan, down 25.12% year-on-year [1] - The net profit attributable to shareholders in Q1 2024 was 269.16 thousand yuan, a decrease of 93.96% compared to the same period last year [1] Asset Management and Strategy - The company is actively working to optimize asset utilization due to increased asset size and management challenges [2] - Strategies include rapid switching of production lines in multi-functional workshops and the "going out" strategy focusing on the UK and Malaysia [2] - The company aims to enhance domestic base development through external orders while maintaining high-quality sustainable growth [2] Industry Trends - The company anticipates a slowdown in the "de-inventory" trend in the agricultural protection industry in the second half of the year [2] - The recovery of patented products is expected to outpace that of generic drugs, which will be reflected in next year's financial statements [2] International Operations - The UK subsidiary faced losses in 2023 due to internal loan interest and low capacity utilization from the "de-inventory" trend [2] - The company is reviewing the UK operations to improve management and will adjust product offerings to enhance local production efficiency [2] Competitive Landscape - The company is preparing for challenges post-patent expiration by developing new technologies and optimizing production processes [3] - It believes that China's comprehensive supply chain and waste management systems provide a competitive edge against Indian competitors [3] Pharmaceutical and New Energy Business - The pharmaceutical segment is expanding its client base and enhancing R&D capabilities, having passed FDA and PMDA audits in 2023 [3] - New energy products like lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide are in trial production, with a focus on optimizing processes to reduce costs [3]

北京市嘉源律师事务所 关于联化科技股份有限公司 2023年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 致：联化科技股份有限公司 北京市嘉源律师事务所 关于联化科技股份有限公司 嘉源(2024)-04-385 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股 东大会规则》（以下简称"《股东大会规则》"）等现行有效的法律、行政法规、 部门规章、规范性文件（以下简称"法律法规"）以及《联化科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，指派本所律师对公司2023 年度股东大会（以下简称"本次股东大会"）进行见证，并依法出具本法律意见 书。 为出具本法律意见书，本所指派律师现场见证了本次股东大会，查阅了公司 提供的与本次股东大会有关的文件和资料，并进行了必要的核查和验证。在 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-034 联化科技股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2024年5月22日（星期三）13时30分 2、会议地点：浙江省台州市黄岩区世纪大道3号黄岩耀达酒店会议室 3、会议召集人：联化科技股份有限公司董事会 4、会议方式：现场投票与网络投票相结合的方式 5、现场会议主持人：董事长王萍女士 6、会议的召集、召开与表决程序符合《公司法》《上市公司股东大会规则》《深 圳证券交易所股票上市规则》等法律、法规及规范性文件和《公司章程》的规定。 （二）会议出席情况 出席现场会议的股东共2名，代表有表决权的股份数4,721,070股，占公司有表决 权股份总数的0.5180%；参加网络投票的股东共13名，代表有表决权的股份数 239,926,312股，占公司有表决权股份总数的26.3270%；参加现场与 ...

联化科技股份有限公司投资者关系活动记录表 证券代码：002250 证券简称：联化科技 编号：20240508 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及人员 姓名 参与公司 2023 年度业绩说明会的投资者 时间 2024 年 5 月 8 日 (周三) 下午 15:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 用网络远程的方式召开业绩说明会 上市公司接待人员姓 名 董事长、总裁王萍女士，独立董事俞寿云先生，高级副总裁、 董秘陈飞彪先生及财务总监薛云轩先生 投资者关系活动主要 内容介绍 1、英国子公司这些年持续亏损，花了三十亿左右真金白银，索 性断臂求生？临海基地规划发展什么内容？目前情况怎样？ 您好，公司会努力做好英国子公司的生产经营工作。目前 公司临海基地规划为公司新能源、新材料等相关项目。截至目 前，临海基地的公共设施建设、产品产线建设和与客户沟通工 作正在按计划进行中。谢谢！ 2、英国子公司从 2017 年收购亏损至今，是否有出售或扭亏为 盈计划？ 您好 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.2 RMB per 10 shares to all shareholders, based on the total share capital excluding repurchased shares of 11,913,139 shares[5]. - The board of directors has approved the profit distribution plan, emphasizing the commitment to shareholder returns[5]. - The company has implemented a stable profit distribution policy, with a cash dividend amount of ¥18,226,662.34, representing 100% of the total profit distribution[194]. - The net profit for the parent company in 2023 was ¥16,843,405.01, after allocating ¥1,684,340.50 to surplus reserves[194]. - The total distributable profit available for shareholders was ¥2,189,322,816.79, with the previous year's undistributed profit being ¥2,266,488,377.88[194]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits[194]. - The company’s cash dividend per 10 shares is ¥0.2, with no stock dividends issued[194]. - The company’s cash dividend policy aligns with its mature development stage and aims to enhance investor returns[194]. Financial Performance - The company’s operating revenue for 2023 was ¥6,442,152,833.02, a decrease of 18.10% compared to ¥7,865,465,550.37 in 2022[21]. - The net profit attributable to shareholders for 2023 was -¥465,243,948.60, representing a decline of 166.76% from ¥696,838,439.53 in 2022[21]. - The net cash flow from operating activities increased by 68.67% to ¥1,077,406,421.58 in 2023, up from ¥638,760,811.35 in 2022[21]. - The total assets at the end of 2023 were ¥13,907,013,976.85, a decrease of 7.34% from ¥15,008,660,120.73 at the end of 2022[21]. - The net assets attributable to shareholders decreased by 7.33% to ¥6,441,634,199.75 at the end of 2023, down from ¥6,951,263,314.13 at the end of 2022[21]. - The basic earnings per share for 2023 was -¥0.5039, compared to ¥0.7548 in 2022, reflecting a significant decline[21]. - The total profit for 2023 was CNY -402.05 million, a decline of 142.57% year-on-year, while the net profit attributable to shareholders was CNY -465.24 million, a decrease of 166.76% compared to the previous year[68]. Research and Development - The company has a focus on research and development of new products and technologies, aiming to enhance its market position[5]. - The pharmaceutical R&D team expanded in 2023, with over 1/3 of employees holding master's or doctoral degrees, and developed more than 10 continuous process projects and 4 continuous photocatalysis projects[62]. - The company established a new R&D service (CRO) base in 2023 to enhance R&D capabilities and expanded its technical fields, including PROTAC, Linker, and GalNAc[62]. - The R&D team is committed to optimizing existing product processes and increasing the development of high-value and differentiated products to enhance core competitiveness[61]. - The company is actively participating in the development of innovative drugs, with a pipeline of clinically promising products in phases II and III[43]. - The company has established a multi-level R&D platform to promote rapid integration of process technology and engineering technology, improving market competitiveness of customized and proprietary products[57]. Market and Industry Trends - The company operates in the plant protection industry, which is characterized by high R&D barriers for patented products and intense competition in the non-patented product market[31]. - The global carbon reduction goals are driving the agricultural protection industry to develop more efficient and low-toxicity products, with an increasing demand for biological products and green production processes[32]. - The CDMO model is increasingly adopted by pharmaceutical companies to outsource R&D and production, providing more opportunities for CDMO firms to participate in the entire product supply chain[34]. - The domestic MAH system has created new opportunities for the pharmaceutical market and CDMO companies, enhancing their innovation and production capabilities[35]. - The demand for functional chemicals is rapidly expanding due to increasing needs for battery chemicals and new materials, driven by geopolitical factors and carbon neutrality strategies[36]. - The lithium battery market in China is projected to reach a shipment volume of 886 GWh in 2023, reflecting a year-on-year growth of 35%[131]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[5]. - The report outlines the company's governance structure and responsibilities of the board and management[5]. - The board of directors consists of seven members, with three independent directors, ensuring compliance with legal and regulatory requirements[160]. - The company has a transparent information disclosure system, ensuring timely and accurate communication with investors[161]. - The company has established a comprehensive internal control system, covering 15 subsidiaries, to ensure effective governance and compliance[198]. - The company has engaged in capital increases and employee stock ownership plans for its subsidiaries, including Shanghai Baofeng and Taizhou Lianhua[197]. Operational Performance and Strategy - The company is committed to compliance with safety, health, environment, and quality standards in its operations[5]. - The company is actively involved in the production of fine chemicals and pharmaceutical intermediates, contributing to its revenue streams[5]. - The company is focused on developing electronic chemicals, battery chemicals, and high-performance polymer materials, while maintaining a stable and high-quality product line[44]. - The company aims to maintain a competitive edge through continuous investment in engineering equipment upgrades and innovative technology applications[63]. - The company is focusing on process optimization for clients' existing products to maintain market competitiveness and has successfully applied unique technical capabilities in various projects[75]. - The company aims to build an end-to-end supply chain management system to maximize production resource utilization while ensuring order delivery capabilities[71]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 5,771, with 1,086 in the parent company and 4,685 in major subsidiaries[189]. - The company conducted 7,551 internal offline training sessions in 2023, totaling 12,230 hours and reaching 199,166 participants[192]. - Online learning totaled 136,668 hours with 40,272 participants in 2023[192]. - The company spent nearly 4.66 million yuan on various internal and external training consulting fees in 2023[192]. - The professional composition of employees includes 3,573 production personnel, 1,532 technical personnel, and 54 sales personnel[189]. - The company emphasizes a fair compensation policy based on internal, external, and individual fairness[190]. Future Outlook and Strategic Goals - The company aims to maintain industrial business revenue at no less than 2023 levels in 2024, although this target is subject to macroeconomic and market conditions[134]. - The company plans to enhance its core competitiveness by focusing on innovation and expanding its CDMO business, particularly in biopesticides and pharmaceuticals[133]. - In 2024, the company will continue to optimize costs in its pesticide business by improving production processes and introducing advanced environmental treatment technologies[138]. - The pharmaceutical segment is expected to grow steadily, with multiple client validation projects completed in 2023 and new project verifications planned for 2024[140]. - The company is committed to sustainable development and will strengthen its SHEQ&C management system to enhance its core competitiveness in safety, health, and environmental quality[135]. - The company plans to increase its investment in environmental protection and safety measures, which may lead to higher costs but aims to meet stringent regulatory standards[147].

联化科技股份有限公司 2023 年度内部控制评价报告 联化科技股份有限公司 2023 年度内部控制评价报告 联化科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求，结 合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对 2023 年 12 月 31 日公司财务报告内部控制有效性进行了评 价。 一、 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内 部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监 事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有 局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内 部控制变得不恰当，或对控制政 ...